This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acquisition Of Hi-Tech Pharmacal Co., Inc. By Akorn, Inc. May Not Be In The Best Interests Of Hi-Tech Pharmacal Co., Inc. Shareholders

SAN DIEGO and AMITYVILLE, N.Y., Aug. 27, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the acquisition of Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) ("Hi-Tech") by Akorn, Inc. (NASDAQ: AKRX) ("Akorn").  On August 27, 2013, the two companies announced a definitive merger agreement under which Akorn will acquire Hi-Tech for $43.50 in cash for each share of Hi-Tech stock.  The transaction is expected to close in the first quarter of 2014.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Is the Merger Best for Hi-Tech and Its Shareholders?

Robbins Arroyo LLP's investigation focuses on whether the board of directors at Hi-Tech is undertaking a fair process to obtain maximum value and adequately compensate its shareholders in the merger.  

As an initial matter, the $43.50 merger consideration represents a premium of only 23.54% based on Hi-Tech's closing price on August 26, 2013.  That premium is substantially below the average one-day premium of 52.8% for comparable transactions in the past five years.  In addition, Hi-Tech directors and the trusts in which they are trustees, who collectively own 14.3% of the outstanding shares have agreed to:  (i) vote their shares in favor of the merger; (ii) vote against any acquisition proposal or other action that would prevent or delay the merger; and (iii) seek the joinder of certain of their family members to the merger who collectively own an additional 4.3% of the outstanding shares.

Given these facts, Robbins Arroyo is examining Hi-Tech's board of directors' decision to sell the company to Akorn now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects, and whether they are seeking to benefit themselves.  

Hi-Tech shareholders have the option to file a class action lawsuit to secure the best possible price for shareholders and the disclosure of material information so shareholders can vote on the transaction in an informed manner.  Hi-Tech shareholders interested in information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/hi-tech-pharmacal-co-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs